Terms: = Gastric cancer AND SMARCA4, hSNF2b, 6597, P51532, BRG1, SNF2L4, SNF2, SWI2, FLJ39786, BAF190, SNF2LB, SNF2-BETA, ENSG00000127616 AND Treatment
13 results:
1. [Clinicopathological features of gastric alpha-fetoprotein-producing adenocarcinoma with SWI/SNF complex deletion].
Yang JZ; Guo XX; Xu C; Hou YY; Yuan W
Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):52-57. PubMed ID: 38178747
[No Abstract] [Full Text] [Related]
2. PICH Activates Cyclin A1 Transcription to Drive S-Phase Progression and Chemoresistance in gastric cancer.
Ye H; Shi W; Yang J; Wang L; Jiang X; Zhao H; Qin L; Qin J; Li L; Cai W; Guan J; Yang H; Zhou H; Yu Z; Sun H; Jiao Z
Cancer Res; 2023 Nov; 83(22):3767-3782. PubMed ID: 37646571
[TBL] [Abstract] [Full Text] [Related]
3. smarca4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co-amplification.
Pries K; Krüger S; Heckl S; Behrens HM; Röcken C
Cancer Med; 2023 May; 12(9):10423-10437. PubMed ID: 36916408
[TBL] [Abstract] [Full Text] [Related]
4. Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients.
Yin YX; Ling YH; Wei XL; He CY; Wang BZ; Hu CF; Lin WP; Nie RC; Chen JW; Lin JL; Zhou J; Xie JJ; Yun JP; Xie D; Xue LY; Cai MY
Front Immunol; 2022; 13():973085. PubMed ID: 36591236
[TBL] [Abstract] [Full Text] [Related]
5. Identification and treatment of smarca4 Deficient Poorly Differentiated gastric Carcinoma.
Bhat V; Koneru M; Knapp K; Joneja U; Morrison J; Hong YK
Am Surg; 2023 Nov; 89(11):4987-4989. PubMed ID: 36533880
[TBL] [Abstract] [Full Text] [Related]
6. [gastric SWI/SNF complex deletion-associated undifferentiated carcinoma with rhabdoid phenotype: a clinicopathological and molecular analysis].
Jin YP; Wang L; Wang Y; Wu DY; Zhang H; Xia QX
Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1229-1234. PubMed ID: 36480831
[No Abstract] [Full Text] [Related]
7. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
[TBL] [Abstract] [Full Text] [Related]
8. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
[TBL] [Abstract] [Full Text] [Related]
9. HOXC-AS1-MYC regulatory loop contributes to the growth and metastasis in gastric cancer.
Dong Y; Li X; Lin Z; Zou W; Liu Y; Qian H; Jia J
J Exp Clin Cancer Res; 2019 Dec; 38(1):502. PubMed ID: 31870402
[TBL] [Abstract] [Full Text] [Related]
10. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M
Int J Mol Med; 2018 Aug; 42(2):713-725. PubMed ID: 29786110
[TBL] [Abstract] [Full Text] [Related]
11. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract] [Full Text] [Related]
12. Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients.
Fuse N; Nagahisa-Oku E; Doi T; Sasaki T; Nomura S; Kojima T; Yano T; Tahara M; Yoshino T; Ohtsu A
Gastric Cancer; 2013 Jul; 16(3):324-8. PubMed ID: 22910898
[TBL] [Abstract] [Full Text] [Related]
13. Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state.
Yamamichi N; Inada K; Ichinose M; Yamamichi-Nishina M; Mizutani T; Watanabe H; Shiogama K; Fujishiro M; Okazaki T; Yahagi N; Haraguchi T; Fujita S; Tsutsumi Y; Omata M; Iba H
Cancer Res; 2007 Nov; 67(22):10727-35. PubMed ID: 18006815
[TBL] [Abstract] [Full Text] [Related]
